BeiGene (Germany) Today
| 49BA Stock | EUR 290.00 2.00 0.68% |
PerformanceSoft
| Odds Of DistressLow
|
BeiGene is trading at 290.00 as of the 5th of February 2026. This is a 0.68 percent decrease since the beginning of the trading day. The stock's lowest day price was 290.0. BeiGene has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 7th of November 2025 and ending today, the 5th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the Peoples Republic of China, the United States, and internationally. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the Peoples Republic of China. The company has 101.81 M outstanding shares. More on BeiGene
Moving against BeiGene Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BeiGene Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BeiGene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BeiGene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President Development | Wang Lai | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
BeiGene's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BeiGene's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsBeiGene utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into BeiGene's leverage profile, showing how much of BeiGene's resources are funded through borrowing.
| |||||
BeiGene (49BA) is traded on Frankfurt Exchange in Germany and employs 11,000 people. BeiGene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 32.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BeiGene operates under Biotechnology sector and is part of Health Care industry. The entity has 101.81 M outstanding shares.
BeiGene has accumulated about 1.54 B in cash with (140.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.49.
Check BeiGene Probability Of Bankruptcy
Ownership AllocationBeiGene holds a total of 101.81 Million outstanding shares. 30% of BeiGene outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BeiGene Ownership Details
BeiGene Historical Income Statement
BeiGene Stock Against Markets
BeiGene Stock Analysis Notes
About 17.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the Peoples Republic of China, the United States, and internationally. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the Peoples Republic of China. BEIGENE LTD is traded on Frankfurt Stock Exchange in Germany. For more info on BeiGene please contact the company at 41 61 685 19 00 or go to https://beonemedicines.com.BeiGene Quarterly Total Revenue |
|
BeiGene Investment Alerts
| The company reported the revenue of 3.81 B. Net Loss for the year was (644.79 M) with profit before overhead, payroll, taxes, and interest of 4.29 B. | |
| BeiGene has accumulated about 1.54 B in cash with (140.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.49. | |
| Roughly 17.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Early Trading Movement BeiGene Rises Over 4 percent as NHC Launches New Pricing Mechanism for Innovative Drugs - |
BeiGene Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 32.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.BeiGene Profitablity
BeiGene's profitability indicators refer to fundamental financial ratios that showcase BeiGene's ability to generate income relative to its revenue or operating costs. If, let's say, BeiGene is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BeiGene's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BeiGene's profitability requires more research than a typical breakdown of BeiGene's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12. Management Efficiency
BeiGene has return on total asset (ROA) of 0.0169 % which means that it generated a profit of $0.0169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0181 %, meaning that it generated $0.0181 on every $100 dollars invested by stockholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BeiGene's Non Current Assets Total are most likely to increase significantly in the upcoming years. The BeiGene's current Non Currrent Assets Other is estimated to increase to about 17 M, while Total Assets are projected to decrease to roughly 4.6 B.Evaluating the management effectiveness of BeiGene allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BeiGene Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 5th of February, BeiGene shows the Risk Adjusted Performance of 0.059, downside deviation of 2.07, and Mean Deviation of 1.84. BeiGene technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BeiGene mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation to decide if BeiGene is priced correctly, providing market reflects its regular price of 290.0 per share.BeiGene Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. BeiGene Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe BeiGene price patterns.
BeiGene Outstanding Bonds
BeiGene issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BeiGene uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BeiGene bonds can be classified according to their maturity, which is the date when BeiGene has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BeiGene Predictive Daily Indicators
BeiGene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BeiGene stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BeiGene Forecast Models
BeiGene's time-series forecasting models are one of many BeiGene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BeiGene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in BeiGene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
BeiGene Corporate Management
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chan Lee | General VP | Profile | |
| Xiaodong Wang | Chairman CoFounder | Profile | |
| Mi Zhou | Director Relations | Profile | |
| Marcello Damiani | Chief Officer | Profile | |
| Liza Heapes | Head Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BeiGene Stock please use our How to Invest in BeiGene guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.